AGIOS PHARMACEUTICALS, INC.

# Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals is a biopharmaceutical company focused on discovering and developing medicines targeting cellular metabolism disorders. The company's primary product is PYRUKYND (mitapivat), a pyruvate kinase activator approved for treating hemolytic anemias in adults with pyruvate kinase deficiency. PYRUKYND is also in phase 3 clinical development for sickle cell disease and is being studied in pediatric populations with PK deficiency. The company has also advanced AQVESME, a treatment for transfusion-dependent and non-transfusion-dependent thalassemia in adult patients.

The company's clinical pipeline includes additional pyruvate kinase modulators and compounds targeting rare hematologic and metabolic disorders. Tebapivat, another PK activator, is in development for lower-risk myelodysplastic syndrome and sickle cell disease. Agios is also developing AG-181, a phenylalanine hydroxylase stabilizer for phenylketonuria, and AG-236, an in-licensed siRNA therapeutic targeting TMPRSS6 for polycythemia vera.

Based in Cambridge, Massachusetts, Agios operates with approximately 539 full-time employees. The company is incorporated in Delaware and trades on the Nasdaq under the ticker AGIO.